CSIMarket
 
Allovir Inc   (ALVR)
Other Ticker:  
 
 
Price: $0.7319 $-0.05 -6.034%
Day's High: $0.7678 Week Perf: -1.09 %
Day's Low: $ 0.73 30 Day Perf: 6.07 %
Volume (M): 543 52 Wk High: $ 6.12
Volume (M$): $ 397 52 Wk Avg: $2.51
Open: $0.73 52 Wk Low: $0.62



 Market Capitalization (Millions $) 83
 Shares Outstanding (Millions) 114
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -169
 Cash Flow (TTM) (Millions $) -28
 Capital Exp. (TTM) (Millions $) 0

Allovir Inc
Allovir Inc is a biotechnology company that specializes in the development of T-cell immunotherapies for the treatment of viral diseases and cancer. The company's main focus is on developing allogeneic, off-the-shelf T-cell therapies that can be used to target and destroy viruses or cancer cells in patients. Allovir's approach involves genetically modifying T-cells to express specific receptors that recognize and attack infected or malignant cells, providing a targeted and potent therapeutic approach. The company aims to address critical unmet needs in patients with life-threatening viral infections or cancer who may not be eligible for other treatment options.


   Company Address: 1100 Winter Street Waltham 2451 MA
   Company Phone Number: 433-2605   Stock Exchange / Ticker: NASDAQ ALVR
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Announcement

Investor Alert: AlloVir Inc. Faces Securities Class Action Deadline, Rosen Law Firm Urges Shareholders to Take Legal Action

Published Fri, Mar 15 2024 9:48 PM UTC

Investors who have suffered losses exceeding $100,000 in AlloVir, Inc. (NASDAQ: ALVR) securities are encouraged to seek legal counsel before the crucial March 19, 2024 deadline, according to Rosen Law Firm. The global investor rights law firm issued a reminder to purchasers of AlloVir securities during the Class Period, spanning from March 22, 2022, to December 21, 2023.Duri...

Announcement

AlloVir, Inc. Faces Securities Lawsuit: A Call for Transparency and Accountability in Biopharmaceutical Investing.

Published Mon, Feb 26 2024 5:27 PM UTC

AlloVir, Inc. Faces Class Action Lawsuit for Securities Law Violations - Investors Advised to Seek Legal Assistance from Levi & KorsinskyThe pharmaceutical industry has always been a lucrative market, attracting investors from all corners of the world. However, with the potential for high returns also comes the risk of securities law violations, as recently evidenced by the ...

Clinical Study

The AlloVir Predicament: A Pivotal Twist in the Phase 3 Posoleucel Clinical Program

Published Fri, Dec 22 2023 12:00 PM UTC

The biotech industry is known for its high-stakes gambles and unpredictable outcomes. In recent developments, AlloVir announced its decision to terminate its three Phase 3 posoleucel studies. The decision, weighed after separate DSMB (Data and Safety Monitoring Board) futility analyses, stems from the prognosis that the studies were unlikely to achieve their primary endpoint...

Allovir Inc

ALVR's Performance in the Third Quarter of 2023 Reveals Concerns Among Shareholders and Investors2.



In an unexpected turn of events, Allovir Inc, a renowned biotechnology and pharmaceuticals company, has reported modifications to its revenue during the July to September 30, 2023 reporting cycle. These alterations have left investors and market participants wondering about the future performance of the company.
The financial results for this period revealed an operating shortfall of $-46.961 million, significantly deteriorating from the $-42.95 million reported in the third quarter of the previous year. This operating shortfall highlights a potential strain on the company's financial position, raising concerns among shareholders and investors alike.

Allovir Inc

Allovir Inc. Reports Surge in Outlays During Q2 2023 Earnings Season; Shareholders Surprised by Operational Losses



Allovir Inc, a prominent player in the Biotechnology & Pharmaceuticals industry, has recently experienced a noteworthy gain in shares, reflecting positive market sentiment. However, it is crucial to analyze the implications of this gain in relation to the company's overall financial performance and future prospects. In this article, we will delve into the recent financial results and discuss how they may impact Allovir Inc going forward.
1. Solid Gain in Share Price:
Allovir Inc shares have recorded a significant gain of 5.23% over the last five trading days, signaling investor optimism. This positive market response suggests that shareholders have confidence in the company's direction and growth potential.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com